Recent advances in immunotherapy have demonstrated clinical activity of PD‐1 or programmed cell death ligand 1 (PD‐L1) immune checkpoint inhibitors in urothelial carcinoma.28, 29. This evidence concerns the gene PDCD1 and urothelial carcinoma.